Van Agthoven M, Segeren CM, Buijt I, Uyl-de Groot CA, Van der Holt B, Lokhorst HM, Sonneveld P. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. Eur J Cancer 2004; 40: 1159-1169.
Van Agthoven M, Uyl-de Groot CA, Sonneveld P, Hagenbeek A. Economic assessment in the management of non-Hodgkin’s lymphoma. Expert Opin Pharmacother 2004; 5: 2529-2548.
Van Agthoven M, Wittebol S, Budel LM, Uyl-de Groot CA, Kramer MHH. Overleving van patiënten met agressief non-hodgkinlymfoom: geen verschil tussen eerstelijnsbehandeling in klinisch prospectief gerandomiseerd fase-III-onderzoek en eerstelijnsbehandeling buiten studieverband. Ned Tijdschr Geneesk 2004; 148: 88-92.
Al MJ, Brouwer WBF. Stimuleren doelmatig gebruik van zuurpompremmers in de onderhoudsbehandeling. TSG 2004; 82: 191-195.
Al MJ, Feenstra T, Brouwer WBF. Decision makers’ views on health care objectives and budget constraints: results from a pilot study.Health Policy 2004; 70: 33-48.
Van den Berg B, Brouwer WBF, Koopmanschap MA. Economic evaluation of informal healthcare: an overview of methods ans applications. Eur J Health Econ 2004; 5:36-45.
Baltussen R, Knai C, Sharan M. Iron fortification and iron supplementation are cost-effective interventions to reduce iron deficiency in four subregions of the world. J Nutr 2004; 134: 2678-84.
Baltussen R, Sylla M, Mariotti SP. Cost-effectiveness analysis of cataract surgery: a global and regional analysis. Bull World Health Organ 2004; 82: 338-45.
Beersen N, Bart de Bruijn JH, Dekkers MA, Ten Have P, Hekster GB, Redekop WK, Spincemaille GH, Theuvenet PJ, Berg M, Klazinga NS. Developing a national continuous quality improvement system for neuromodulation treatment in The Netherlands. Jt Comm J Qual Saf 2004; 30: 310-21.
Bernelot Moens HJ, Van Croonenborg JJ, Al MJ, Van den Bemt PMLA, Lourens J, Numans ME. Richtlijn ‘NSAID-gebruik en preventie van maagschade’. Ned Tijdschr Geneeskd 2004; 148: 604-608.
Brouwer WBF, Van Exel NJA. Discounting in decision-making: the consistency argument revisited empirically. Health Policy 2004; 67: 187-194.
Brouwer WBF, Van Exel NJA, Van de Berg B, Koopmanschap MA, Dinant HJ, Van den Bos GAM. The burden of caregiving: Evidence on objective burden, subjective burden and quality of life impacts in informal caregivers for patients with Rheumatoid Arthritis. Arthritis Rheum 2004; 51: 570-577.
Brouwer WBF, Van Nooten FE, Rutten FFH. Nog veel te winnen met betere richtlijnen. TSG 2004; 8: 523-526.
Brouwer WBF, Rutten FFH. Bittere pillen. Medisch Contact 2004; 59: 1114-1116.
Brouwer WBF, Rutten FFH. Modernisering GVS: een contradictio in terminis? TSG 2004; 7: 463-466.
Bueving HJ, Bernsen RMD, De Jongste JC, Van Suijlekom-Smit LWA, Rimmelzwaan GF, Osterhaus ADME, Rutten-van Mölken MPMH, Thomas S, Van der Wouden JC. Influenza vaccination in children with astma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 2004; 169: 488-493.
Bueving HJ, Bernsen RMD, De Jongste JC, Van Suijlekom-Smit LWA, Rimmelzwaan GF, Osterhaus ADME, Rutten-van Mölken MPMH, Thomas S, Van der Wouden JC. Griepvaccinatie bij kinderen met astma: een gerandomiseerd dubbelblind placebo-gecontroleerd onderzoek. Huisarts en Wetenschap 2004; 47: 491-497.
Bueving HJ, Bernsen RMD, De Jongste JC, Van Suijlekom-Smit LWA, Rimmelzwaan GF, Osterhaus ADME, Rutten-van Mölken MPMH, Thomas S, Van der Wouden JC. Does influenza vaccination exacerbate asthma in children? Vaccine 2004; 23: 91-96.
Doorduijn JK, Buijt I, Van der Holt B, Van Agthoven M, Sonneveld P, Uyl-de Groot CA. Economic evaluation of prophylactic granulocyte colony-stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma. Haematologica 2004; 89: 1109-1117.
Van Exel NJA, Van den Berg B, Koopmanschap MA, Van den Bos GAM, Brouwer WBF. Informele zorg: een goed om te waarderen. TSG 2004; 82: 236-242.
Van Exel NJA, Brouwer WBF, Van den Berg B, Koopmanschap MA, Van den Bos GAM. What really matters: an inquiry into the relative importance of dimensions of informal caregiver burden. Clin Rehabil 2004; 18: 683-693.
Van Exel NJA, Scholte op Reimer WJM, Koopmanschap MA. Assessment of post-stroke quality of life in cost-effectiveness studies: the usefulness of the Barthel Index and the EuroQoL-5D. Qual Life Res 2004; 13: 427-433.
Van Exel NJA, Scholte op Reimer WJM, Brouwer WBF, Van den Berg B, Koopmanschap MA, Van den Bos GAM. Instruments for assessing the burden of informal caregiving for stroke patients in clinical practice: a comparison of CSI, CRA, SCQ and self-related burden. Clin Rehabil 2004; 18: 203-214.
Groot MT, Van Agthoven M, Löwenberg B, Willemze R, Uyl-de Groot CA. De rol van kostenanalysen in de evaluatie van de ontwikkeling van medische technologieën. De casus allogene stamceltransplantaties. Ned Tijdschr Geneeskd 2004; 148: 480-484.
Groot MT, Huijgens PC, Wijermans PJ, Uyl-de Groot CA. Costs of multiple myeloma and associated skeletal-related events in The Netherlands. Expert Rev Pharmacoeconomics Outcomes Res 2004; 4: 565-572.
Hakkaart-Van Roijen L, Hoeijenbos MB, Regeer EJ, Ten Have M, Nolen WA, Veraart CP, Rutten FF. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands. Acta Psychiatr Scand. 2004; 110: 383-92.
Hakkaart-van Roijen L, Moll van Charante EP, Bindels PJE, Yzermans CJ, Rutten FFH. A cost study of a general practitioner hospital in the Netherlands. Eur J Gen Pract 2004; 10: 45-49.
Johns B, Baltussen R. Accounting for the cost of scaling-up health interventions. Health Econ 2004; 13: 1117-1124.
Koopmanschap MA, Van Exel NJA, Van den Bos GAM, Van den Berg B, Brouwer WBF. The desire for support and respite care: preferences of Dutch informal caregivers. Health Policy 2004; 68: 309-320.
Korthals-de Bos IBC, Smidt N, Van Tulder MW, Rutten-van Mölken MPMH, Adèr HJ, Van der Windt DAWM, Assendelft WJJ, Bouter LM. Cost effectiveness of interventions for lateral epicondylitis.: results form a randomised controlled trial in primary care. Pharmacoeconomics 2004; 22: 185-195.
McDonnell J, Goverde AJ, Vermeiden JPW. The place of the crossover design in infertility trials: a maximum likelihood approach. Hum Reprod 2004; 19: 2537-44.
Moens HJ, van Croonenborg JJ, Al MJ, van den Bemt PM, Lourens J, Numans ME; Working Group, Kwaliteitsinstituut voor de Gezondheidszorg CBO. Richtlijn ‘NSAID gebruik en preventie van maagschade’.Ned Tijdschr Geneeskd 2004; 148: 604-8.
Nijdam WM, Levendag PC, Noever I, Uyl-de Groot CA, Van Agthoven M. Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate. Int J Radiat Oncol Biol Phys 2004; 59: 488-494.
Van Nooten F, Brouwer W. The influence of subjective expectations about length and quality of life on time trade-off answers. Health Econ 2004; 13: 819-823.
Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004; 98: 883-891.
Oostenbrink JB, Rutten-van Mölken MPMH, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241-249.
Ortegon MM, Redekop WK, Niessen LW. Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Diabetes Care. 2004; 27: 901-907.
Peeters AJ, Van Gogh CD, Goor KM, Verdonck-De Leeuw IM, Langendijk JA, Mahieu HF. Health status and voice outcome after treatment for T1a glottic carcinoma. Eur Arch Otorhinolaryngol 2004; 261: 534-540.
Poley MJ, Bouwmans CAM, Hanff LM, Roos PJ, Van Ineveld BM. Efficiency of different systems for medication distribution in an academic children’s hospital in the Netherlands. Pharm World Sci 2004; 26: 83-89.
Poley MJ, Stolk EA, Tibboel D, Molenaar JC, Busschbach JJ. Short term and long term health related quality of life after congenital anorectal malformations and congenital diaphragmatic hernia. Arch Dis Child 2004; 89: 836-841.
De Raad J, Redekop WK. A comparison between two systems for pre-employment medical assessment in the Royal Netherlands Army by a randomized, controlled study. Mil Med. 2004; 169: 437-43.
Redekop WK. Does improved glycaemic control lead to a better short-term quality of life in diabetes mellitus type 2? J Postgrad Med 2004; 50: 194.
Redekop WK, Stolk EA, Kok E, Lovas K, Kalo Z, Busschbach JJ. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004; 30: 549-56.
Regeer EJ, Ten Have M, Rosso ML, Hakkaart-Van Roijen L, Vollebergh W, Nolen WA. Prevalence of bipolar disorder in the general population: a Reappraisal Study of the Netherlands Mental Health Survey and Incidence Study. Acta Psychiatr Scand. 2004; 110: 374-82.
Rutten FFH. Health technology assessment and policy from the economic perspective. Int J Technol Assess Health Care 2004; 20: 67-70.
Rutten FFH. L’impatto della riforma sanitaria e la politica farmaceutica in Olanda. Economia Politica del Farmaco 2004; 2: 4-9.
Rutten FFH. The impact of healthcare reform in the Netherlands. Pharmacoeconomics 2004; 22 Suppl 2: 65-71.
Schut FT, Brouwer WBF. De preferente apotheker? Jazeker! ESB 2004; 89: 266-269.
Sendi P, Al MJ, Battegay M. Optimising the performance of an outpatient setting. Swiss Med Wkly 2004; 134: 44-9.
Sendi P, Al MJ, Gafni A, Birch S. Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations. Soc Sci Med 2004; 58: 1853-1855.
Sendi P, Al MJ, Rutten FFH. Portfolio theory and cost-effectiveness analysis: a further discussion. Value Health 2004; 7: 595-601.
Sendi P, Al MJ, Zimmermann H. A risk-adjusted approach to comparing the return on investment in health care programs. Int J Health Care Finance Econ 2004; 4: 199-210.
Sendi P & Brouwer WBF. Leisure time in economic evaluation: theoretical and practical considerations. Expert Review Pharmacoeconomics Outcomes Research 2004; 4: 1-3.
Stolk EA, Van Donselaar G, Brouwer WBF, Busschbach JJ. Reconciliation of economic concerns and health policy : illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics. 2004; 22: 1097-1107.
Uyl-de Groot CA, Gelderblom-den Hartog J, Derksen JGM, Symons EA, Buijt I, Van der Velden J, Van Lindert ACM. Cost-effectiveness and quality of life of granulocyte-colony stimulating factor (filgrastim) after radical vulvectomy and bilateral inguino-femoral lymphadenectomy: results of a randomized clinical trial. Eur J Obstet Gynec Repr Biol 2004; 114: 77-82.
Van de Ven WPMM, Van Vliet RCJA, Lamers LM. Health-adjusted premium subsidies in the Netherlands.Health Affairs 2004; 23: 45-55.
Van Wijngaarden JDH, Scholte op Reimer WJM, Van Exel NJA, Klazinga NS, Huijsman R. Coordination between caregivers from different organizations: more continuity, better results. Acta Hospitalia 2004; 44: 21-38.
De Wit A, Brouwer WBF. Economische evaluatie van GVO-programma’s. Belangrijk, lastig en te weinig gedaan. TSG 2004; 82: 129-132.